Skip to content

Ezetimibe

Ezetimibe is a cholesterol-lowering medicine that reduces cholesterol absorption in the small intestine. Ezetimibe Tablets contains the ingredient alone, while Roszet combines it with rosuvastatin.

Ezetimibe Tablets

Hyperlipidaemia, Primary Hypercholesterolaemia

10mg

Indicated to address elevated blood cholesterol to relieve arterial plaque risk and support cardiovascular wellness.

From$1.62/ tabletView

Roszet

Primary Hyperlipidaemia

40mg + 10mg

Designed to support dual lipid reduction to manage hypercholesterolaemia and target arterial plaque risk.

From$4.58/ tabletView

Key points

  • Ezetimibe limits intestinal absorption of cholesterol.
  • The single-ingredient record is a 10 mg tablet.
  • Roszet combines 10 mg ezetimibe with 40 mg rosuvastatin.
  • Liver and muscle symptoms require added attention when a statin is present.

The 10 mg single-ingredient record

Ezetimibe Tablets connects with hyperlipidaemia and primary hypercholesterolaemia. Official medicine information also covers selected inherited lipid disorders, including homozygous familial hypercholesterolaemia and sitosterolaemia.

The ingredient works at the intestinal cholesterol transporter. This is distinct from reducing cholesterol production in the liver, the main pathway targeted by statins.

Roszet brings the two pathways together

Roszet contains rosuvastatin as its second ingredient. Rosuvastatin inhibits HMG-CoA reductase in the liver, while ezetimibe reduces intestinal absorption. Both records appear in cholesterol management, but only Roszet has this two-mechanism identity.

Ezetimibe information highlights liver disease and unexplained muscle pain or weakness. Statin-containing products add a stronger muscle and liver safety context, so the co-ingredient must remain visible whenever Roszet is discussed.

Further reading